BTIG Starts Esperion Therapeutics (ESPR) at Buy

BTIG analyst Thomas Shrader initiates coverage on Esperion Therapeutics (NASDAQ: ESPR) with a Buy rating and a price target of $82.00.

The analyst comments "Esperion calls itself the lipid management company based on the development of bempedoic acid (BA) an inhibitor of ATP-citrate lyase that works in the same pathway as the statins. The clinical development of BA has demonstrated the drug reduces cholesterol in patients on any therapeutic background. The remaining question is how safe is the drug? The share price of Esperion should track the consensus view of the answer."

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $44.94 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)